1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Forest Laboratories Holdings Acquires Saphris

Divestiture • Medical Products

Forest Laboratories Holdings Acquires Saphris

On December 2, 2013, Forest Laboratories Holdings acquired medical products company Saphris from Merck Sharp & Dohme B.V. for 240M USD

Acquisition Context
  • This is Forest Laboratories Holdings’ 1st transaction in the Medical Products sector.
  • This is Forest Laboratories Holdings’ largest (disclosed) transaction.
  • This is Forest Laboratories Holdings’ 1st transaction in the United States.

Explore All 633 Divestiture Medical Products Deals - Search the Database Free


M&A Deal Summary
Date December 2, 2013
Target Saphris
Sector Medical Products
Buyer(s) Forest Laboratories Holdings
Sellers(s) Merck Sharp & Dohme B.V.
Deal Type Divestiture
Deal Value 240M USD

Target Company

Saphris

United States
Saphris is approved by the U.S. Food and Drug Administration for the treatment of schizophrenia in adults, and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults, as monotherapy or as adjunctive therapy with either lithium or valproate.
Explore More Deals

Browse All 215,158 Deals

FILTER BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Search Free

Buyer Overview 1

Buyer

Forest Laboratories Holdings

United States
Category Company
Sector Medical Products
DESCRIPTION

Forest Laboratories Holdings Ltd., a wholly owned subsidiary of Forest Laboratories. A pharmaceutical drugs company.

Deal Context for Buyer #
Overall 1 of 1
Sector: Medical Products 1 of 1
Type: Divestiture 1 of 1
Country: United States 1 of 1
Year: 2013 1 of 1
Size (of disclosed) 1 of 1

Seller Profile 1

SELLER

Merck Sharp & Dohme B.V.

Haarlem, Netherlands
Category Company
Founded 1954
Sector Medical Products
DESCRIPTION

Merck Sharp & Dohme B.V., a wholly owned subsidiary of Merck & Co., Inc. (NYSE:MRK). Merck Sharp & Dohme B.V provides medicines for diabetes, High blood pres pressure and rheumatic disease patients.

Deal Context for Seller #
Overall 2 of 3
Sector: Medical Products 1 of 1
Type: Divestiture 2 of 3
Country: United States 1 of 2
Year: 2013 2 of 2
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2013-11-08 Merck Sharp & Dohme - Pharma­ceutical Skin Care Product

Sweden

Merck Sharp & Dohme - Pharma­ceutical Skin Care Product is a lotion, based on active substance propylene glycol, used for dry skin, atopic dermatitis and psoriasis.

Sell -
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2015-10-21 Vree Health

Annandale, New Jersey, United States

Vree Health LLC is a provider of healthcare technology solutions.

Sell -

Explore Related M&A Activity

Medical Products M&A - Divestiture M&A Deals - United States M&A - 2013 M&A

Mergr

Solution for

Product

Company

Legal